Treatment of muscle weakness in neuromuscular disorders

被引:6
|
作者
Finsterer, Josef [1 ]
Zarrouk-Mahjoub, Sinda [2 ]
机构
[1] Krankenanstalt Rudolfstiftung Wien, Vienna, Austria
[2] Pasteur Inst Tunis, Genom Platform, Tunis, Tunisia
关键词
Neuromuscular; myopathy; neuropathy; neuronopathy; myasthenia; genetics; treatment; therapy; DUCHENNE MUSCULAR-DYSTROPHY; IDIOPATHIC INFLAMMATORY MYOPATHIES; HYPOKALEMIC PERIODIC PARALYSIS; RANDOMIZED CONTROLLED-TRIAL; STEM-CELL TRANSPLANTATION; DOUBLE-BLIND; MYASTHENIA-GRAVIS; CREATINE SUPPLEMENTATION; ELECTRICAL-STIMULATION; NEURALGIC AMYOTROPHY;
D O I
10.1080/14737175.2016.1206471
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: Weakness is one of the predominant clinical manifestations of neuromuscular disorders (NMDs), which strongly influences daily life, prognosis, and outcome of affected patients. One of the major therapeutic goals in NMD-patients is to completely resolve muscle weakness. Various treatment options are available and include physical therapy, electrotherapy, diet, drugs, avoidance or withdrawal of muscle-toxic and weakness-inducing agents, detoxification, stem-cell-therapy, plasma-exchange, respiratory therapy, or surgery. Most accessible to treatment is weakness from immune-mediated neuropathies, immune-mediated transmission-disorders, and idiopathic immune myopathies.Areas covered: This manuscript aims to summarize and discuss recent findings and future perspectives concerning the treatment of muscle weakness in NMDs. Data were obtained by a literature search in databases such as PubMed and Current-Contents.Expert commentary: Weakness is most easily treatable in acquired NMDs and in hereditary myopathies and neuropathies beneficial treatment options are also available. Research needs to be encouraged and intensified to further expand the spectrum of treatment options for weakness.
引用
收藏
页码:1383 / 1395
页数:13
相关论文
共 50 条
  • [31] Neuromuscular weakness and collapse
    Platt, SR
    Garosi, LS
    [J]. VETERINARY CLINICS OF NORTH AMERICA-SMALL ANIMAL PRACTICE, 2004, 34 (06) : 1281 - +
  • [32] SCANNING EMG IN NORMAL MUSCLE AND IN NEUROMUSCULAR DISORDERS
    STALBERG, E
    DIOSZEGHY, P
    [J]. ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY, 1991, 81 (06): : 403 - 416
  • [33] Inspiratory muscle training in children with neuromuscular disorders
    Human, Anri
    Corten, Lieselotte
    Lozano-Ray, Eleonora
    Morrow, Brenda M.
    [J]. SOUTH AFRICAN JOURNAL OF PHYSIOTHERAPY, 2024, 80 (01)
  • [34] Needle muscle biopsy in the investigation of neuromuscular disorders
    Magistris, MR
    Kohler, A
    Pizzolato, G
    Morris, MA
    Baroffio, A
    Bernheim, L
    Bader, CR
    [J]. MUSCLE & NERVE, 1998, 21 (02) : 194 - 200
  • [35] Apoptosis and muscle fibre loss in neuromuscular disorders
    Tews, DS
    [J]. NEUROMUSCULAR DISORDERS, 2002, 12 (7-8) : 613 - 622
  • [36] Muscle development genes: their relevance in neuromuscular disorders
    Muntoni, F
    Brown, S
    Sewry, C
    Patel, K
    [J]. NEUROMUSCULAR DISORDERS, 2002, 12 (05) : 438 - 446
  • [37] Vaccination in patients with disorders of the muscle and neuromuscular junction
    Esposito, Susanna
    Passera, Sofia
    [J]. EXPERT REVIEW OF VACCINES, 2013, 12 (11) : 1341 - 1349
  • [38] Muscle ultrasound in neuromuscular disorders: utility and limits?
    Musumeci, O.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 44 - 44
  • [39] DISORDERS OF THE NEUROMUSCULAR-JUNCTION AND MUSCLE - FOREWORD
    LUTTGEN, PJ
    [J]. SEMINARS IN VETERINARY MEDICINE AND SURGERY-SMALL ANIMAL, 1989, 4 (02): : 107 - 107
  • [40] Recent developments in muscle imaging of neuromuscular disorders
    Fischer, Dirk
    Bonati, Ulrike
    Wattjes, Mike P.
    [J]. CURRENT OPINION IN NEUROLOGY, 2016, 29 (05) : 614 - 620